Group items tagged

2015 Global Retinoblastoma Drugs Industry Report is a professional and in-depth research report on the world's major regional market conditions of the Retinoblastoma Drugs industry, focusing on the main regions (North America, Europe and Asia) and the main countries (United States, Germany, Japan and China).

According to market forecasts, the global renal denervation market will witness significant growth over the next six years, jumping from USD 15.5 million in 2012 to USD 171.7 million by 2019, at a CAGR of 41%. This will mainly be attributable to the intervention's expected approval in major countries. It is stated that across 10 major markets in the major global economies (the US, France, Germany, Italy, Spain, UK, Japan, Brazil, China and India), only the European Union has approved the use of renal denervation.